loading page

New-Onset Seizures After Bamlanivimab Infusion
  • Saahil Jumkhawala,
  • Jessica Bente
Saahil Jumkhawala
Saint Barnabas Health Care System
Author Profile
Jessica Bente
Saint Barnabas Health Care System
Author Profile

Abstract

Since the beginning of the COVID-19 pandemic, industry and healthcare providers have investigated methodologies to manage infection of SARS-CoV-2. One treatment breakthrough has been the introduction of monoclonal antibodies to prevent worsening SARS-CoV-2 infection in non-hospitalized patients diagnosed with COVID-19. These monoclonal antibodies, like bamlanivimab, bind to the SARS-CoV-2 spike protein and prevent its ability to binding to human ACE2 receptors. This is a case of a 91 year-old man with no prior seizure history who developed new-onset seizures after bamlanivimab infusion.
02 May 2021Submitted to British Journal of Clinical Pharmacology
04 May 2021Submission Checks Completed
04 May 2021Assigned to Editor
10 May 2021Reviewer(s) Assigned
27 May 2021Review(s) Completed, Editorial Evaluation Pending
02 Jun 2021Editorial Decision: Revise Major
28 Jun 20211st Revision Received
01 Jul 2021Submission Checks Completed
01 Jul 2021Assigned to Editor
01 Jul 2021Review(s) Completed, Editorial Evaluation Pending
16 Jul 2021Editorial Decision: Revise Minor
28 Jul 20212nd Revision Received
30 Jul 2021Submission Checks Completed
30 Jul 2021Assigned to Editor
30 Jul 2021Review(s) Completed, Editorial Evaluation Pending
08 Aug 2021Editorial Decision: Accept
Mar 2022Published in British Journal of Clinical Pharmacology volume 88 issue 3 on pages 1395-1397. 10.1111/bcp.15066